livertransplantationimmunosuppression

由 S Poudel 著作 · 2024 — There are two phases in liver transplant immunosuppression therapy, i.e. the induction and maintenance phases. The induction phase or early IS therapy, ...

由 CS Park 著作 · 2023 — Liver transplantation (LT) has become the preferred treatment for conditions like end-stage liver failure and hepatocellular carcinoma.

由 J Lerut 著作 · 2023 · 被引用 11 次 — Immunosuppressive handling is crucial for allograft and patient survival. During the early years of transplantation, steroids and azathioprine were the only ...

由 T Di Maira 著作 · 2020 · 被引用 96 次 — The main causes of mortality late after liver transplant are associated with prolonged use of IS medications, and clear evidence exists about ...

由 AJ Montano-Loza 著作 · 2023 · 被引用 19 次 — The transplanted liver can modulate the immu- nological system of the recipient to promote tolerance, thus offering the potential for less ...

2023年12月4日 — This topic will discuss initiating immunosuppression following liver transplantation and maintaining long-term immunosuppressive therapy.

由 M Rodríguez-Perálvarez 著作 · 2014 · 被引用 115 次 — Calcineurin inhibitors (CNIs) are the mainstay of immunosuppression after liver transplantation. Tacrolimus is the most frequently used because of reduced acute ...

由 BE Tasdogan 著作 · 2019 · 被引用 40 次 — Evidence suggests that TAC is the main immunosuppressive agent in LT patients. A meta-analysis comparing two CNIs concluded that TAC reduces 1-year mortality, ...